10-K/A: ZyVersa Therapeutics Files Amendment to 2023 Annual Report, Addressing Internal Control Weaknesses

ZyVersa Therapeutics has filed an amendment to its 2023 annual report to clarify existing language and update the number of outstanding shares, while also addressing identified material weaknesses in internal controls.

Summary

• ZyVersa Therapeutics filed an amendment to its 2023 annual report on Form 10-K to clarify certain sections and update the number of outstanding shares.
• The amendment restates Item 9A of Part II and Item 15 of Part IV of the original 2023 10-K to clarify existing language.
• The cover page of the 2023 10-K was also amended to update the number of outstanding shares of common stock as of May 10, 2024, which is 834,896.
• The filing includes new certifications by the principal executive officer and principal financial officer under Section 302 of the Sarbanes-Oxley Act of 2002.
• The company identified a material weakness in its internal control over financial reporting as of December 31, 2023, related to business process controls and segregation of duties.
• Management is committed to implementing a remediation plan during 2024 to address the identified material weakness.
• The company is an emerging growth company and is taking advantage of certain exemptions under the JOBS Act.

Sentiment

Score: 4

Explanation: The document highlights a material weakness in internal controls, which is a negative signal. However, management's commitment to remediation and the company's status as an emerging growth company provide some mitigating factors.

Positives

• Management is committed to addressing the identified material weakness in internal controls and has a remediation plan in place for 2024.
• The company is taking advantage of exemptions available to emerging growth companies, which can reduce compliance costs.

Negatives

• A material weakness in internal control over financial reporting was identified as of December 31, 2023.
• The company's disclosure controls and procedures were deemed ineffective as of December 31, 2023.

Risks

• The identified material weakness in internal control over financial reporting could lead to potential misstatements in financial reporting.
• The company's reliance on exemptions for emerging growth companies may reduce transparency for investors.
• Failure to remediate the internal control weakness could lead to further issues with financial reporting.

Future Outlook

Management expects to complete the development and implementation of its remediation plan during 2024 to address the identified material weakness in internal controls.

Management Comments

• Peter Wolfe, Chief Financial Officer, certified that the report does not contain any untrue statement of a material fact.
• Stephen C. Glover, Chief Executive Officer, certified that the report does not contain any untrue statement of a material fact.
• Management concluded that the company's disclosure controls and procedures were ineffective as of December 31, 2023, due to a material weakness.

Industry Context

The filing is a standard regulatory requirement for public companies, particularly those that have identified internal control weaknesses. The focus on internal controls is a common theme in the current regulatory environment.

Comparison to Industry Standards

• Many companies, especially smaller ones, face challenges in maintaining robust internal controls, particularly in the early stages of their public listing.
• The identification of a material weakness is not uncommon, but the speed and effectiveness of the remediation plan are critical for investor confidence.
• Companies like ZyVersa, which are emerging growth companies, often have less mature internal control systems compared to larger, more established companies.

Corporate Governance

Stakeholder Impact

• Shareholders may be concerned about the identified material weakness in internal controls.
• Employees involved in financial reporting may be affected by the remediation plan.
• Creditors may be concerned about the reliability of the company's financial statements.

Next Steps

• Management will implement a remediation plan to address the material weakness in internal controls during 2024.
• The company will continue to monitor and evaluate the effectiveness of its internal controls.

Key Dates

Keywords

internal controls, financial reporting, material weakness, amendment, Sarbanes-Oxley Act, emerging growth company, remediation plan, disclosure controls, Form 10-K, ZyVersa Therapeutics